Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 11, 2014, Pages 1266-1275

  Dulai, P S ^a   Gleeson, M W ^a   Taylor, D ^a   Holubar, S D ^a   Buckey, J C ^a   Siegel, C A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAROTRAUMA; BLURRED VISION; CLINICAL EFFECTIVENESS; CROHN DISEASE; EARDRUM PERFORATION; HUMAN; HYPERBARIC OXYGEN; INFLAMMATORY BOWEL DISEASE; INFORMATION PROCESSING BIAS; MENTAL DISEASE; MIDDLE EAR DISEASE; MIDDLE EAR PRESSURE; PATIENT SAFETY; PRIORITY JOURNAL; PSYCHOLOGICAL INTOLERANCE; REVIEW; SELECTION BIAS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; HYPERBARIC OXYGENATION; TREATMENT OUTCOME;

EID: 84900016174     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12753     Document Type: Review

References (51)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.e1-3.
4. Rutgeerts P, Van Assche G, Sandborn WJ, et al,. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-11.e2.
5. Sandborn WJ, Feagan BG, Stoinov S, et al,. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
6. Siegel CA, Marden SM, Persing SM, et al,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.
7. Siegel CA, Hur C, Korzenik JR, et al,. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-24.
8. Dulai PS, Siegel CA, Dubinsky MC,. Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2013; 19: 2927-36.
9. Dulai PS, Thompson KD, Blunt HB, et al,. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014; doi: 10.1016/j.cgh.2014.01.021 [Epub ahead of print].
10. Speit G, Dennog C, Eichhorn U, et al,. Induction of heme oxygenase-1 and adaptive protection against the induction of DNA damage after hyperbaric oxygen treat-ment. Carcinogenesis 2000; 21: 1795-9.
11. Gu GJ, Li YP, Peng ZY, et al,. Mechanism of ischemic tolerance induced by hyperbaric oxygen preconditioning involves upregulation of hypoxia-inducible factor-1alpha and erythropoietin in rats. J Appl Physiol 2008; 104: 1185-91.
12. Peng Z, Ren P, Kang Z, et al,. Up-regulated HIF-1alpha is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. Brain Res 2008; 1212: 71-8.
13. Furuta GT, Turner JR, Taylor CT, et al,. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 2001; 193: 1027-34.
14. Tjarnstrom J, Wikstrom T, Bagge U, et al,. Effects of hyperbaric oxygen treatment on neutrophil activation and pulmonary sequestration in intestinal ischemia-reperfusion in rats. Eur Surg Res 1999; 31: 147-54.
15. Yang ZJ, Bosco G, Montante A, et al,. Hyperbaric O2 reduces intestinal ischemia-reperfusion-induced TNF-alpha production and lung neutrophil sequestration. Eur J Appl Physiol 2001; 85: 96-103.
16. Yamashita M, Yamashita M,. Hyperbaric oxygen treatment attenuates cytokine induction after massive hemorrhage. Am J Physiol Endocrinol Metab 2000; 278: E811-6.
17. Benson RM, Minter LM, Osborne BA, et al,. Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages. Clin Exp Immunol 2003; 134: 57-62.
18. Weisz G, Lavy A, Adir Y, et al,. Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease. J Clin Immunol 1997; 17: 154-9.
19. Alex J, Laden G, Cale AR, et al,. Pretreatment with hyperbaric oxygen and its effect on neuropsychometric dysfunction and systemic inflammatory response after cardiopulmonary bypass: a prospective randomized double-blind trial. J Thorac Cardiovasc Surg 2005; 130: 1623-30.
20. Karhausen J, Furuta GT, Tomaszewski JE, et al,. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114: 1098-106.
21. Colgan SP, Curtis VF, Campbell EL,. The inflammatory tissue microenvironment in IBD. Inflamm Bowel Dis 2013; 19: 2238-44.
22. Naito Y, Takagi T, Yoshikawa T,. Heme oxygenase-1: a new therapeutic target for inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl. 1): 177-84.
23. Glover LE, Colgan SP,. Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology 2011; 140: 1748-55.
24. American Gastroenterological Association medical position statement. perianal Crohn's disease. Gastroenterology 2003; 125: 1503-7.
25. Sandborn WJ, Fazio VW, Feagan BG, et al,. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30.
26. Plafki C, Peters P, Almeling M, et al,. Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med 2000; 71: 119-24.
27. Clarke RE, Tenorio LM, Hussey JR, et al,. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys 2008; 72: 134-43.
28. Sipahi AM, Damiao AO, de Sousa MM, et al,. Hyperbaric oxygen: a new alternative in the treatment of perianal Crohn's disease. Rev Hosp Clin Fac Med Sao Paulo 1996; 51: 189-91.
29. Takeshima F, Makiyama K, Doi T,. Hyperbaric oxygen as adjunct therapy for Crohn's intractable enteric ulcer. Am J Gastroenterol 1999; 94: 3374-5.
30. Di Girolamo M,. Hyperbaric oxigen (HBO) therapy in Crohn's cutaneous disease (CCD): our experience in patients non responder at biological therapy. Dig Liver Dis 2013; 45S: S146-7.
31. Ben Bouali A, Burtin P, Delaby J, et al,. Indications of hyperbaric oxygen for the treatment of severe ulcerative colitis? [French] Place De L'oxygene Hyperbare Dans Le Traitement Des Colites Ulcereuses Graves? Medecine et Chirurgie Digestives 1990; 19: 340.
32. Buchman AL, Fife C, Torres C, et al,. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol 2001; 33: 337-9.
33. Demirturk L, Ozel M, Yazgan Y, et al,. Therapeutic efficacy of hyperbaric oxygenation in ulcerative colitis refractory to medical treatment. J Clin Gastroenterol 2002; 35: 286-7.
34. Gurbuz AK, Elbuken E, Yazgan Y, et al,. A different therapeutic approach in patients with severe ulcerative colitis: hyperbaric oxygen treatment. South Med J 2003; 96: 632-3.
35. Nelson EW Jr, Bright DE, Villar LF,. Closure of refractory perineal Crohn's lesion. Integration of hyperbaric oxygen into case management. Dig Dis Sci 1990; 35: 1561-5.
36. Brady CE 3rd, Cooley BJ, Davis JC,. Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen. Gastroenterology 1989; 97: 756-60.
37. Kuroki K, Masuda A, Uehara H, et al,. A new treatment for toxic megacolon. Lancet 1998; 352: 782.
38. Green MS, Purohi M, Sadacharam K, et al,. Efficacy of hyperbaric oxygen in patients with Crohn's disease: two case reports. Undersea Hyperb Med 2013; 40: 201-4.
39. Iezzi LE, Feitosa MR, Medeiros BA, et al,. Crohn's disease and hyperbaric oxygen therapy. Acta Cir Bras 2011; 26 (Suppl. 2): 129-32.
40. Colombel JF, Mathieu D, Bouault JM, et al,. Hyperbaric oxygenation in severe perineal Crohn's disease. Dis Colon Rectum 1995; 38: 609-14.
41. Lavy A, Weisz G, Adir Y, et al,. Hyperbaric oxygen for perianal Crohn's disease. J Clin Gastroenterol 1994; 19: 202-5.
42. Karkumov M, Nikolov N, Georgiev L, et al,. Hyperbaric oxygenation as a part of the treatment of chronic ulcerohemorrhagic colitis. Vutr Boles 1991; 30: 78-80.
43. Grigor'eva GA, Poliakova LV, Golysheva IV,. Experience of preservation remission in inflammatory bowel diseases. Eksp Klin Gastroenterol 2011; 9: 132-5.
44. Pagoldh M, Hultgren E, Arnell P, et al,. Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study. Scand J Gastroenterol 2013; 48: 1033-40.
45. Nizet V, Johnson RS,. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009; 9: 609-17.
46. Clambey ET, McNamee EN, Westrich JA, et al,. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012; 109: E2784-93.
47. Hegazi RA, Rao KN, Mayle A, et al,. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med 2005; 202: 1703-13.
48. Al-Waili NS, Butler GJ,. Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action. ScientificWorldJournal 2006; 6: 425-41.
49. Thom SR,. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011; 127 (Suppl. 1): 131S-41S.
50. Thom SR,. Effects of hyperoxia on neutrophil adhesion. Undersea Hyperb Med 2004; 31: 123-31.
51. Rothfuss A, Radermacher P, Speit G,. Involvement of heme oxygenase-1 (HO-1) in the adaptive protection of human lymphocytes after hyperbaric oxygen (HBO) treatment. Carcinogenesis 2001; 22: 1979-85.